← Back to headlines
U.S. FDA approves first-line use of Boehringer Ingelheim's lung cancer drug
Boehringer's Hernexeos was one of the 18 drugs selected so far for the FDA Commissioner's National Priority Voucher Program that allows speedy process and cuts the review time to one to two months from the typical 10 to 12 months
27 Feb, 11:49 — 27 Feb, 11:49
